Mandelic acid derivatives and their use as thrombin inhibitors
AssigneeAstraZeneca AB
InventorTord Inghardt
Life of this patent
Estimating the term…
Abstract
There is provided a compound of formula (I) wherein Ra, R1, R2, Y and R3 have meanings given in the description and pharmaceutically-acceptable derivatives (including prodrugs) thereof, which compounds and derivatives are useful as, or are useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is required (e.g., thrombosis) or as anticoagulants.
Claims1
A pharmaceutical composition adapted for oral administration which is in the form of a gelling matrix modified-release system comprising a hydrophilic gelling component and the compound Ph(3-Cl)(5-OCHF2)—(R)CH(OH)C(O)-Aze-Pab(OMe).
Dependencies are inferred from the claim text.